INLYTA

This brand name is authorized in Austria, Australia, Brazil, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States

Active ingredients

The drug INLYTA contains one active pharmaceutical ingredient (API):

1 Axitinib UNII C9LVQ0YUXG - AXITINIB

Axitinib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2 and VEGFR-3. These receptors are implicated in pathologic angiogenesis, tumour growth, and metastatic progression of cancer. Axitinib has been shown to potently inhibit VEGF-mediated endothelial cell proliferation and survival. Read about Axitinib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
INLYTA Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC
INLYTA	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01EK01	Axitinib	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
Discover more medicines within L01EK01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 10539Q, 10540R, 10556N, 10572K
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 522720020083617, 522720020083717
Country: CA	Health Products and Food Branch	Identifier(s): 02389630, 02389649
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): H5250513
Country: EE	Ravimiamet	Identifier(s): 1593301, 1593312, 1593323, 1593334, 1593345, 1593356, 1623967, 1623978, 1623989, 1623990, 1624003, 1624014
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 12777002, 12777005
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 103854, 599010
Country: FR	Base de données publique des médicaments	Identifier(s): 61357910, 64922489, 67939209, 69083347
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 215059, 215062, 245079, 245082, 392402
Country: HK	Department of Health Drug Office	Identifier(s): 62088, 62089
Country: IE	Health Products Regulatory Authority	Identifier(s): 88116, 88117
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 7169, 7321
Country: IT	Agenzia del Farmaco	Identifier(s): 042233015, 042233027, 042233039, 042233041, 042233054, 042233066, 042233078, 042233080, 042233092, 042233104, 042233116, 042233128
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291027F1029, 4291027F2025
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1067711, 1067712, 1067713, 1067714, 1067715, 1067716, 1075260, 1075261, 1075262, 1075263, 1075264, 1075265
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 104442, 104450, 114650
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 15630, 15631
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100084494, 100208499, 100285070, 100285086
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W64813001, W64813002, W64813003, W64814001, W64814002, W64814003
Country: SG	Health Sciences Authority	Identifier(s): 14321P, 14322P
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 15833011H, 15833012H, 15833013H, 15833014H
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8681308099181, 8681308099198, 8681308099204, 8681308099211, 8681308099228, 8681308099235, 8681308099754, 8681308099761
Country: US	FDA, National Drug Code	Identifier(s): 0069-0145, 0069-0151, 63539-026, 63539-044